Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading on Nasdaq under the ticker LGST, is a clinical-stage biopharmaceutical company focused on developing off-the-shelf T-cell receptor-directed cell therapies targeting infectious diseases and oncology. The company reached its current public status through a SPAC business combination and filed an 8-K current report with the SEC on February 25, 2026, reflecting ongoing disclosure obligations as a post-combination public entity. Operating in the healthcare and biotechnology sector, Tevogen Bio is advancing a pipeline of precision immunology candidates designed to address high unmet medical need. Investors and analysts tracking LGST and the broader SPAC healthcare cohort can access full filing history, deal terms, and comparative data by signing up at SpacDesk.